Literature DB >> 32338945

Using multivariate base rates of low scores to understand early cognitive declines on the uniform data set 3.0 Neuropsychological Battery.

Andrew M Kiselica1, Troy A Webber2, Jared F Benge1.   

Abstract

OBJECTIVE: Low neuropsychological test scores are commonly observed even in cognitively healthy older adults. For batteries designed to assess for and track cognitive decline in older adults, documenting the multivariate base rates (MBRs) of low scores is important to differentiate expected from abnormal low score patterns. Additionally, it is important for our understanding of mild cognitive impairment and preclinical declines to and determine how such score patterns predict future clinical states.
METHOD: The current study utilized Uniform Data Set Neuropsychological Battery 3.0 (UDS3NB) data for 5,870 English-speaking, older adult participants from the National Alzheimer's Coordinating Center from 39 Alzheimer's disease Research Centers from March 2015 to December 2018. MBRs of low scores were identified for 2,608 cognitively healthy participants that had completed all cognitive measures. The association of abnormal MBR patterns with subsequent conversion to mild cognitive impairment and dementia were explored.
RESULTS: Depending on the operationalization of "low" score, the MBR of demographically adjusted scores ranged from 1.40 to 79.2%. Posttest probabilities using MBR methods to predict dementia status at 2-year follow up ranged from .06 to .33, while posttest probabilities for conversion to mild cognitive impairment (MCI) ranged from .12-.32.
CONCLUSIONS: The data confirm that abnormal cognitive test scores are common among cognitively normal older adults. Using MBR criteria may improve our understanding of MCI. They may also be used to enrich clinical trial selection processes through recruitment of at-risk individuals. (PsycInfo Database Record (c) 2020 APA, all rights reserved).

Entities:  

Year:  2020        PMID: 32338945      PMCID: PMC7484046          DOI: 10.1037/neu0000640

Source DB:  PubMed          Journal:  Neuropsychology        ISSN: 0894-4105            Impact factor:   3.295


  60 in total

Review 1.  Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines.

Authors:  Irene Litvan; Jennifer G Goldman; Alexander I Tröster; Ben A Schmand; Daniel Weintraub; Ronald C Petersen; Brit Mollenhauer; Charles H Adler; Karen Marder; Caroline H Williams-Gray; Dag Aarsland; Jaime Kulisevsky; Maria C Rodriguez-Oroz; David J Burn; Roger A Barker; Murat Emre
Journal:  Mov Disord       Date:  2012-01-24       Impact factor: 10.338

2.  Comparing actual to estimated base rates of "abnormal" scores on neuropsychological test batteries: implications for interpretation.

Authors:  Brian L Brooks; Grant L Iverson
Journal:  Arch Clin Neuropsychol       Date:  2009-12-16       Impact factor: 2.813

3.  Frequency and bases of abnormal performance by healthy adults on neuropsychological testing.

Authors:  David J Schretlen; S Marc Testa; Jessica M Winicki; Godfrey D Pearlson; Barry Gordon
Journal:  J Int Neuropsychol Soc       Date:  2008-05       Impact factor: 2.892

4.  Memory improvement following induced hyperinsulinemia in Alzheimer's disease.

Authors:  S Craft; J Newcomer; S Kanne; S Dagogo-Jack; P Cryer; Y Sheline; J Luby; A Dagogo-Jack; A Alderson
Journal:  Neurobiol Aging       Date:  1996 Jan-Feb       Impact factor: 4.673

5.  American Academy of Clinical Neuropsychology consensus conference statement on uniform labeling of performance test scores.

Authors:  Thomas J Guilmette; Jerry J Sweet; Nancy Hebben; Deborah Koltai; E Mark Mahone; Brenda J Spiegler; Kirk Stucky; Michael Westerveld
Journal:  Clin Neuropsychol       Date:  2020-02-10       Impact factor: 3.535

Review 6.  Current concepts in mild cognitive impairment.

Authors:  R C Petersen; R Doody; A Kurz; R C Mohs; J C Morris; P V Rabins; K Ritchie; M Rossor; L Thal; B Winblad
Journal:  Arch Neurol       Date:  2001-12

7.  Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type.

Authors:  J C Morris
Journal:  Int Psychogeriatr       Date:  1997       Impact factor: 3.878

Review 8.  Measurement in cross-cultural neuropsychology.

Authors:  Otto Pedraza; Dan Mungas
Journal:  Neuropsychol Rev       Date:  2008-09-24       Impact factor: 7.444

9.  External validation is necessary in prediction research: a clinical example.

Authors:  S E Bleeker; H A Moll; E W Steyerberg; A R T Donders; G Derksen-Lubsen; D E Grobbee; K G M Moons
Journal:  J Clin Epidemiol       Date:  2003-09       Impact factor: 6.437

10.  Alzheimer's disease drug development pipeline: 2019.

Authors:  Jeffrey Cummings; Garam Lee; Aaron Ritter; Marwan Sabbagh; Kate Zhong
Journal:  Alzheimers Dement (N Y)       Date:  2019-07-09
View more
  7 in total

1.  An initial exploration of the convergent and ecological validity of the UDS 3.0 neuropsychological battery in Parkinson's Disease.

Authors:  RoShunna Lea; Jared F Benge; Charles H Adler; Thomas G Beach; Christine M Belden; Nan Zhang; Holly A Shill; Erika Driver-Dunckley; Shyamal H Mehta; Alireza Atri
Journal:  J Clin Exp Neuropsychol       Date:  2022-02-09       Impact factor: 2.475

2.  Examining racial disparities in the diagnosis of mild cognitive impairment.

Authors:  Andrew M Kiselica; Ellen Johnson; Kaleea R Lewis; Kate Trout
Journal:  Appl Neuropsychol Adult       Date:  2021-09-23       Impact factor: 2.248

3.  Empirically defining the preclinical stages of the Alzheimer's continuum in the Alzheimer's Disease Neuroimaging Initiative.

Authors:  Andrew M Kiselica
Journal:  Psychogeriatrics       Date:  2021-04-22       Impact factor: 2.440

4.  How impaired is too impaired? Exploring futile neuropsychological test patterns as a function of dementia severity and cognitive screening scores.

Authors:  Andrew M Kiselica; Ellen Johnson; Jared F Benge
Journal:  J Neuropsychol       Date:  2021-03-03       Impact factor: 2.864

5.  A Comparison of Operational Definitions for Mild Cognitive Impairment.

Authors:  Alexandra Polcher; Steffen Wolfsgruber; Oliver Peters; Lutz Frölich; Jens Wiltfang; Johannes Kornhuber; Michael Hüll; Eckart Rüther; Piotr Lewczuk; Wolfgang Maier; Frank Jessen; Michael Wagner
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

6.  Neuropsychological Equivalence of the Clinical Diagnosis of Mild Cognitive Impairment in the National Alzheimer's Coordinating Center Uniform Data Set and Alzheimer's Disease Neuroimaging Initiative.

Authors:  Andrew M Kiselica; Jared F Benge
Journal:  Dement Geriatr Cogn Disord       Date:  2021-06-29       Impact factor: 2.959

7.  An Initial Empirical Operationalization of the Earliest Stages of the Alzheimer's Continuum.

Authors:  Andrew M Kiselica; Alyssa N Kaser; Jared F Benge
Journal:  Alzheimer Dis Assoc Disord       Date:  2021 Jan-Mar 01       Impact factor: 2.357

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.